High Dose Valaciclovir As CMV Prophylaxis in Allogeneic Hematopoietic Stem Cell Recipients at High Risk of CMV Reactivation

被引：0
|
作者：
Douglas, Genevieve
Yong, Michelle K.
Tio, Shio Yen
Chau, Maggie
Sasadeusz, Joe
Slavin, Monica
Xie, Mingdi
Ritchie, David
Chee, Lynette C. Y.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141764
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Risk factors of CMV reactivation post allogeneic haematopoietic stem cell transplantation
    Jaskula, E.
    Drabczak-Skrzypek, D.
    Mlynarczewska, A.
    Sedzimirska, M.
    Bogunia-Kubik, K.
    Lange, A.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S267 - S267
  • [32] Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia
    Luis Pinana, Jose
    Gimenez, Estela
    Dolores Gomez, Maria
    Perez, Ariadna
    Maria Gonzalez, Eva
    Vinuesa, Victor
    Carlos Hernandez-Boluda, Juan
    Montoro, Juan
    Salavert, Miguel
    Tormo, Mar
    Amat, Paula
    Moles, Paula
    Carretero, Carlos
    Balaguer-Rosello, Aitana
    Sanz, Jaime
    Sanz, Guillermo
    Solano, Carlos
    Navarro, David
    JOURNAL OF INFECTION, 2019, 78 (05) : 393 - 401
  • [33] Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant
    Johnsrud, Joyce J.
    Nguyen, Isabelle T.
    Domingo, Walter
    Narasimhan, Balasubramanian
    Efron, Bradley
    Brown, Janice
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (10) : 1963 - 1970
  • [34] Prolonged use of letermovir as CMV reactivation prophylaxis significantly reduces the risk of CMV reactivation in persistently immunocompromised stem cell transplant patients
    Koch, K.
    Osswald, L.
    Miller, I.
    Braitsch, K.
    Goetze, K.
    Bassermann, F.
    Herhaus, P.
    Verbeek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 242 - 242
  • [35] CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
    Chavaz, Lara
    Royston, Lena
    Masouridi-Levrat, Stavroula
    Mamez, Anne-Claire
    Giannotti, Federica
    Morin, Sarah
    Van Delden, Christian
    Chalandon, Yves
    Neofytos, Dionysios
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (04):
  • [36] Letermovir Prophylaxis in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant
    Nguyen, Isabelle T.
    Johnsrud, Joyce J.
    Brown, Janice
    Domingo, Walter
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S347 - S348
  • [37] High dose valaciclovir to prevent cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients
    Lam, Stephanie
    Boan, Peter
    Polistena, Paola
    Cannell, Paul
    Cooney, Julian
    Wright, Matthew
    Purtill, Duncan
    TRANSPLANT INFECTIOUS DISEASE, 2021,
  • [38] Risk Factors for Recurrent CMV Reactivation in CMV Seropositive Recipients Following T Cell Depleted Haematopoietic Stem Cell Transplantation
    Ibrahim, Abeer
    Ingram, Wendy
    Price, Nicola
    Davies, David
    Wilson, Keith
    BLOOD, 2014, 124 (21)
  • [39] IMMUNE POPULATIONS PREDICT CONTROL OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Diaz-Fernandez, Paula
    Garcia de Soria, Valle Gomez
    Sevilla-Montero, Javier
    Marcos-Jimenez, Ana
    Serra Lopez-Matencio, Jose Maria
    Cardenoso, Laura
    Figuera Alvarez, Angela
    de la Camara, Rafael
    Munoz-Calleja, Cecilia
    BONE MARROW TRANSPLANTATION, 2024, 59 : 431 - 431
  • [40] Pre-Transplant Ganciclovir and High-Dose Valacyclovir Prophylaxis Decrease Incidence of CMV Reactivation In High-Risk Seropositive UCBT Recipients
    Milano, Filippo
    Pergam, Steven
    Xie, Hu
    Gutman, Jonathan
    Riffkin, Ivy
    Chow, Victor
    Newell, Laura
    Boeckh, Michael
    Delaney, Colleen
    BLOOD, 2010, 116 (21) : 298 - 298
12345